Stockwatch

Navco Pharmaceuticals Inc
Symbol	NAV
Shares Issued	40,350,441
Close 2024-01-16	C$ 0.04
Market Cap	C$ 1,614,018
Recent Sedar Documents

Navco Pharma completes acquisition of SL Immuno

2024-01-18 16:50 ET - News Release

Subject: NAVCO Pharmaceuticals Inc. Re: News Released for Dissemination Word Document File: '\\swfile\EmailIn\20240118 134257 Attachment Navco - News Release Announcing Closing of SL Immuno Acquisition (FINAL).docx' LEGAL_42871860.2 LEGAL_42871860.2 Navco Pharmaceuticals Inc. Completes Acquisition of SL Immuno Pharma Corp. Vancouver, British Columbia--(January 18, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) ("Navco" or the "Company", formerly, BMGB Capital Corp.) is pleased to announce that, further to its news release dated December 11, 2023, it has completed the acquisition (the "Acquisition") of all the issued and outstanding shares of SL Immuno Pharma Corp. ("SL Immuno") pursuant to the terms of a share exchange agreement dated December 11, 2023 (the "Share Exchange Agreement") between the Company, Navco and the shareholders of SL Immuno (the "SL Immuno Shareholders"). SL Immuno is a pharmaceutical company that is looking to improve drug delivery and natural clean lifestyle options for everyday people. SL Immuno has formulated sublingual strips (the "MunoStrips") infused with some of the most powerful immune-boosting compounds known to science to help maintain immune function and help support the body's metabolism. MunoStrips offer a precise, rapid, discreet, and healthier option to help support immune function. The MunoStrips product line has been scientifically developed to integrate easily into everyday life and most daily activities. Navco will look to get this acquisition, along with its line of Health Canada registered NAVCO BioActive(TM) topical antibacterial skin cleanser and treatment products and NAVCO BioGuard(TM) antiviral oral products, onto pharmaceutical shelves across the country. BioActive(TM) and BioGuard(TM) are revolutionary non-toxic, alcohol and chemical-free and non-flammable nanoproducts that protect against germs and microorganisms. In connection with the Acquisition, the Company issued an aggregate of 16,719,100 common shares in the capital of the Company (the "Payment Shares") pro rata to the SL Immuno Shareholders at a deemed price of $0.05 per Payment Share. For additional details regarding the Acquisition and SL Immuno's business and operations, please refer to the Company's news release dated December 11, 2023,available under the Company's SEDAR+ profile at www.sedarplus.ca. In conjunction with and upon closing of the Acquisition, two members of the Company's Board of Directors, Dr. Akbar Khan and Mr. Peter Espig resigned from the Board of Directors, and SL Immuno nominees, Mr. Jatinder "Jay" Dhaliwal and Ms. Judy Su, were appointed as directors of the Company to fill the vacancies created by those resignations. The Company would also like to take this opportunity to thank Dr. Khan and Mr. Espig for all of their contributions as directors of the Company, and to welcome Mr. Dhaliwal and Ms. Su to its Board. About the Company Navco is a Burlington, Ontario - based company that is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, viruses, fungi and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved products. The Company's pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods-of-action to capitalize on unmet health and product needs using natural & known compounds and nanoparticles with a high degree of efficacy. Target markets include human health & personal skin care, household & institutional products and veterinary health. For additional information, please refer to the Company's disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to it, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; commercialization of the Company's product line; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company assumes no responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. PDF Document File: Attachment Navco - News Release Announcing Closing of SL Immuno Acquisition (FINAL).pdf Navco Pharmaceuticals Inc. Completes Acquisition of SL Immuno Pharma Corp. Vancouver, British Columbia--(January 18, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) ("Navco" or the "Company", formerly, BMGB Capital Corp.) is pleased to announce that, further to its news release dated December 11, 2023, it has completed the acquisition (the "Acquisition") of all the issued and outstanding shares of SL Immuno Pharma Corp. ("SL Immuno") pursuant to the terms of a share exchange agreement dated December 11, 2023 (the "Share Exchange Agreement") between the Company, Navco and the shareholders of SL Immuno (the "SL Immuno Shareholders"). SL Immuno is a pharmaceutical company that is looking to improve drug delivery and natural clean lifestyle options for everyday people. SL Immuno has formulated sublingual strips (the "MunoStrips") infused with some of the most powerful immune-boosting compounds known to science to help maintain immune function and help support the body's metabolism. MunoStrips offer a precise, rapid, discreet, and healthier option to help support immune function. The MunoStrips product line has been scientifically developed to integrate easily into everyday life and most daily activities. Navco will look to get this acquisition, along with its line of Health Canada registered NAVCO BioActiveTM topical antibacterial skin cleanser and treatment products and NAVCO BioGuardTM antiviral oral products, onto pharmaceutical shelves across the country. BioActiveTM and BioGuardTM are revolutionary non-toxic, alcohol and chemical-free and non-flammable nanoproducts that protect against germs and microorganisms. In connection with the Acquisition, the Company issued an aggregate of 16,719,100 common shares in the capital of the Company (the "Payment Shares") pro rata to the SL Immuno Shareholders at a deemed price of $0.05 per Payment Share. For additional details regarding the Acquisition and SL Immuno's business and operations, please refer to the Company's news release dated December 11, 2023,available under the Company's SEDAR+ profile at www.sedarplus.ca. In conjunction with and upon closing of the Acquisition, two members of the Company's Board of Directors, Dr. Akbar Khan and Mr. Peter Espig resigned from the Board of Directors, and SL Immuno nominees, Mr. Jatinder "Jay" Dhaliwal and Ms. Judy Su, were appointed as directors of the Company to fill the vacancies created by those resignations. The Company would also like to take this opportunity to thank Dr. Khan and Mr. Espig for all of their contributions as directors of the Company, and to welcome Mr. Dhaliwal and Ms. Su to its Board. LEGAL_42871860.2 About the Company Navco is a Burlington, Ontario based company that is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, viruses, fungi and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved products. The Company's pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods-of-action to capitalize on unmet health and product needs using natural & known compounds and nanoparticles with a high degree of efficacy. Target markets include human health & personal skin care, household & institutional products and veterinary health. For additional information, please refer to the Company's disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to it, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; commercialization of the Company's product line; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results LEGAL_42871860.2 or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company assumes no responsibility for the accuracy or completeness of such forward- looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. LEGAL_42871860.2